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Abstract 
Palmitoylation of GLUT1 was investigated in brain capillaries. The glucose transporter was shown to be palmitoylated using 
[3H]palmitate labeling and iramunoprecipitation. The labeling was sensitive to methanolic KOH or hydroxylamine hydrolysis, indicating 
the presence of an ester or thioester bond. The released fatty acid was analyzed by reverse-phase HPLC and was identified as 
[3H]palmitate. Specificity of the immunoprecipitation was assessed by competitive inhibition of anti-GLUT1 binding with a synthetic 
C-terminal peptide against which the antibody was raised. In vivo studies were performed using capillaries isolated from control rats, 
streptozotocin-induced diabetic rats and diet-induced hyperglycemic rats. Glycemia was increased 2- and 5-fold in the hyperglycemic and 
diabetic groups, respectively. GLUT1 expression was evaluated in the three groups by Western blot analysis. A 36% decrease in GLUT1 
expression was observed in the diabetic group, while there was no significant variation in GLUT1 expression i  the hyperglycemic group. 
Palmitoylation of GLUT1 was increased in both diet-induced hyperglycemic and diabetic groups. These results suggest that palmitoyla- 
tion may be involved in the regulation of glucose transport activity in hyperglycemia. 
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1. Introduction 
Under normal physiological conditions, glucose is the 
only source of energy utilized by the brain [1]. Entry of 
glucose from the blood to the brain requires its transport 
across the capillary endothelial cells that form the blood- 
brain barrier [2-4]. In thi:~ tissue, glucose uptake is medi- 
ated by the GLUT1 isof0rm of the sodium-independent 
glucose transporter [5,6]. Although the upregulation of 
GLUT1 expression during hypoglycemia has been well 
characterized [6,7], little is known about the different 
events occurring during hyperglycemia. The results ob- 
tained on GLUT1 expression are controversial since differ- 
ent studies have reported a decrease [8-10], no change 
[11,12] or an increase i~L GLUT1 during hyperglycemia 
Abbreviations: BSA, bovine serum albumin; BBBC, blood-brain bar- 
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[13,14]. However, in most studies GLUT1 transport activ- 
ity was decreased. This suggests that GLUT1 activity may 
be directly regulated by a mechanism which could be 
independent of its level of expression. 
Palmitoylation is a post-translational modification which 
is involved in the regulation of the activity of several 
membrane proteins such as p2Y as [15], fl2-adrenergic re- 
ceptor [16], transferrin receptor [17] and rhodopsin [18]. 
GLUT1 has six cysteine residues, several of which are 
located near the cytoplasmic surface of the plasma mem- 
brane [19,20]. Such cysteines are known to be among the 
most common palmitoylation sites [21,22]. In a previous 
study, GLUT1 was found to be palmitoylated in erythro- 
cytes [23]. However, in a recent study, palmitate incorpora- 
tion in this protein could not be demonstrated [24]. A study 
on the palmitoylation of blood-brain barrier capillary pro- 
teins has shown that the major substrate is a 55 kDa 
protein [25]. Since GLUT1, a 55 kDa protein, is strongly 
expressed in brain capillaries [26], the possibility that this 
glucose transporter is palmitoylated was investigated. 
In this study, palmitoylation of the glucose transporter 
(GLUT1) from brain capillaries was characterized. In- 
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creased GLUT1 palmitoylation was observed in both strep- 
tozotocin-induced diabetic and diet-induced hyperglycemic 
rats. These findings suggest hat palmitoylation may be 
involved in the regulation of the activity of the brain 
capillary glucose transporter. 
2. Materials and methods 
2.1. Isolation of blood-brain barrier capillaries 
Brains were isolated from rats and placed in ice-cold 
physiological buffer (PB) containing 147 mM NaCI, 4 mM 
KC1, 3 mM CaC12, 1.2 mM MgC12, 5 mM glucose and 15 
mM Hepes (pH 7.4). Capillaries were isolated as described 
by Dallaire et al. [27]. The final pellet containing purified 
brain capillaries was resuspended in PB containing 1.4% 
sorbitol and 14% glycerol as cryopreservative agents [27]. 
The capillaries were either used immediately or stored in 
liquid nitrogen and used within 1 month. 
enhanced chemiluminescence detection system 
(Amersham). 
2.4. Immunoprecipitation 
Brain capillaries (200 ~g protein in 10 /zl) were lysed 
by addition of 1 ml of 1% Triton X-100, 0.1% SDS, 1% 
BSA, 20 mM Tris (pH 7.5), 150 mM NaC1, and placed 
under agitation for 30 min at room temperature. Lysates 
were transferred to microcentrifuge tubes and centrifuged 
at 12500 × g for 10 min at 4 ° C. Supernatants were trans- 
ferred to new microcentrifuge tubes and incubated 
overnight at 4 ° C with 5 /zl anti-GLUT1 antibody. Protein 
A-Sepharose 4 fast flow (Pharmacia) was added (40 ~1) 
and the incubation continued at 4 ° C for another 5 h. Beads 
were washed once with 1% Triton X-100, 0.1% SDS, 1% 
BSA, 150 mM NaC1, 20 mM Tris (pH 7.5) and three times 
with TBS. The final pellets were prepared for SDS-PAGE 
as described previously, but the samples were placed under 
agitation for 15 min in the sample buffer. 
2.2. SDS-polyacrylamide g l electrophoresis 2.5. Peptide synthesis 
BBBC (blood-brain barrier capillaries) proteins (10 /xg) 
[28] were resuspended in Laemmli's sample buffer con- 
taining 60 mM Tris-HC1 (pH 6.8), 12.5% glycerol, 1% 
SDS, 5 mM /3-mercaptoethanol and 0.05% Bromophenol 
blue. The samples were placed under agitation for 15 min 
in the sample buffer and were loaded on 10 or 12.5% 
acrylamide/bisacrylamide (29.2:0.8) gels [29]. Elec- 
trophoresis was carried out at a constant voltage of 120 V 
for 2 h. The gels were stained with Coomassie Brilliant 
Blue or transferred electrophoretically onto Immobilon-P 
membranes for Western blot analysis. Molecular weight 
determinations were based on a calibration curve prepared 
with the following standards: phosphorylase b (97 kDa), 
bovine serum albumin (66 kDa), ovalbumin (45 kDa), 
carbonic anhydrase (31 kDa), trypsin inhibitor (21 kDa) 
and c~-lactalbumin (14 kDa). 
2.3. Western blot analysis 
Proteins were separated by SDS-PAGE (sodium dode- 
cylsulfate-polyacrylamide gel lectrophoresis) and the pro- 
teins were transferred electrophoretically onto 0.45 /.~M 
pore size Immobilon-P membranes (Millipore). The blots 
were blocked overnight with 10% powdered milk in 20 
mM Tris (pH 7.0), 150 mM NaC1 and 0.2% Tween 20 
(TBST). Polyclonal anti-GLUT1 antibody was kindly pro- 
vided by Dr. W. Pardridge from UCLA or purchased from 
Eastacres (RaGLUTrans) (1:5000) was used as primary 
antibody and incubation was carried out for 2 h at room 
temperature. After four washes in TBST, the blots were 
incubated with anti-rabbit horseradish peroxidase-con- 
jugated antibody (Pierce) (1:1000) for 1 h at room temper- 
ature, washed four times in TBST, and developed with an 
The 15-amino acid peptide CEELFHPLGADSQV was 
synthesized using Fmoc chemistry and an Applied Biosys- 
terns automated peptide synthesizer following the recom- 
mendations of the manufacturer. This peptide corresponds 
to the 14-amino acid C-terminal portion of the human 
erythrocyte glucose transporter (GLUT1) [30], an N-termi- 
nal Cys residue was added to allow coupling of the 
peptide. The peptide was purified on a semi-preparative 
Vydac C18 high performance liquid chromatography col- 
umn and its identity was verified by fast atom bombard- 
ment mass spectrometry. This peptide corresponds to the 
sequence recognized by the anti-GLUT1. 
2.6. Palmitoylation 
Palmitoylation was performed by adding 100 /zg of 
BBBC proteins to an incubation medium containing: 25 
/zM [3H]palmitic acid (150 /~Ci/assay) and 0.1% Triton 
X-100 or BSA in PB (pH 7.4). In some experiments, 
palmitoylation was carried out in PB containing 0.1% 
Triton X-100, 20 mM MgCI2, 20 mM MnCI 2, 20 mM 
ATP and 0.2 mM CoA. The mixture was incubated for 3 h 
at 37°C and the reaction was stopped by the addition of 
lysis buffer for a final concentration of 1% Triton X-100, 
1% BSA, 0.1% SDS, 20 mM Tris (pH 7.5) and 150 mM 
NaC1. The glucose transporter was then immunoprecip- 
itated and proteins resolved by SDS-PAGE, as described 
previously. For fluorography, the gels were treated with 
En3Hance (NEN) and dried. Before exposure, a Kodak 
radiographic film was pre-flashed to obtain 0.1 to 0.2 
absorbance unit. The dried gels were exposed at -80°C 
for 3 to 40 days. The fluorograms were scanned with an 
LKB Ultroscan XL enhanced laser densitometer. In some 
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experiments, the gels were sliced in 2 mm strips placed in 
individual vials. The strips were then treated with NCS 
tissue solubilizer (Amersham) and the palmitate incorpora- 
tion was measured by liquid scintillation counting. 
2. 7. Metabolic labeling with [35S]methionine 
BBBC proteins (100 /xg) were incubated in PB contain- 
ing 0.3 /zM [35S]methionine (30 /zCi/assay). The mixture 
was incubated for 1 h at 37°C and the reaction was 
stopped by the addition of lysis buffer. The glucose trans- 
porter was then immunoprecipitated, the proteins separated 
by SDS-PAGE and the gel treated for fluorography as 
described previously. 
97- 
66- 
45- 
31- 
[3H] Palm 
o X ~ m _ 
I-. El m ~ El 
2.8. Analysis" of labeled fatty acids 
After immunoprecipitation and SDS-PAGE, the ra- 
dioactive fatty acids were liberated from GLUT1 by treat- 
ing the gel slices with 1.5 M KOH in 25% methanol. Fatty 
acids were extracted with chloroform/methanol (2:1) and 
then analyzed on a C-18 reverse phase HPLC column 
(Vydac C18 #100) using a 75-100% acetonitrile gradient 
as described by Christgau et al. [31]. 
2.9. Animal treatments 
Fig. 1. Immunodetection and radiolabeling of GLUT1 using [3H]palmi- 
tare and [35S]methionine. Capillary proteins (100 /xg) were labeled with 
[3H]palmitate for 3 h at 37 ~ C using Triton X-100 (TX) or bovine serum 
albumin (BSA) as palmitate solubilizing agents, or labeled with 
[35S]methionine for1 h at 37 ° C ([35S]Met). At the end of the incubation 
period, the glucose transporter was immunoprecipitated using a poly- 
clonal antibody directed against he C-terminal portion of the protein. 
After separation of immunoprecipitated proteins by SDS-PAGE, the gels 
were treated for fluorography and exposed to preflashed Kodak films for 
82 ([3H]palmitate) or 6 days ([35S]methionine). GLUT1 was also detected 
by Western blot analysis (Blot) with the same antibody as described 
under Materials and methods. 
Male Sprague-Dawley rats (300-400 g) were divided 
into the following three groups: Control (Co), Diabetic 
(Da) and Hyperglycemic (Hy). The first two groups (Co 
and Da) received Purina rat chow and water ad libitum, 
while the third group (Hy) received only a 50% glucose 
solution. Diabetes was induced with a single intraperi- 
toneal injection of streptozotocin (65 mg/kg)  dissolved in 
PB. All animals were killed by decapitation after 14 days 
and brain capillaries were purified as described previously. 
2.10. Blood glucose analysis 
Blood was collected immediately after decapitation and 
the samples placed into glass tubes at room temperature 
for 30 min. The tubes were centrifuged at 5000 × g for 30 
min and glucose concentration was measured in serum 
with a glucose oxidase-peroxidase assay [32]. 
3. Results 
Immunoprecipitation of brain capillary proteins by 
anti-GLUT1 antibody, after pre-incubation of capillaries 
with [3H]palmitate, resulted in the detection of two major 
bands corresponding to proteins with molecular masses 
similar to that of GLUT1, as detected by Western blot 
analysis (Fig. 1). The same immunoprecipitation procedure 
was used with [35S]methionine-labeled capillary proteins 
and revealed labeled bands corresponding to polypeptides 
with the same molecular masses as those detected with 
[3H]palmitate labeling. Palmitoylation was performed us- 
ing either BSA or Triton X-100 as palmitate solubilizing 
agents. In some experiments BSA alone was used because 
it has no disruptive effects on the plasma membrane, in 
order to verify if GLUTI  is palmitoylated in normal 
physiological conditions. The use of BSA alone prevents 
alterations in protein structure or cellular integrity that may 
be caused by detergents. However, since Triton X-100 
resulted in an increased palmitoylation, this condition was 
preferred in several characterization experiments. 
The nature of the linkage between [3H]palmitate and the 
labeled proteins was determined by hydrolysis with hy- 
droxylamine or methanolic KOH treatments (Fig. 2). Ra- 
dioactive labeling was abolished by both treatments ug- 
gesting the presence of an ester or thioester bond. The 
nature of the cleavage products was studied by cutting out 
the portion of the gel corresponding to the immunoprecip- 
itated radiolabeled proteins, treating it with methanolic 
KOH and extracting the resulting supernatant with chloro- 
form/methanol  (1:1). Free fatty acids were resolved by 
HPLC on a reverse-phase column. The cleaved radioactive 
fatty acids eluted from the column with the same retention 
time as unlabeled palmitate (Fig. 3). 
Competitive inhibition of GLUT1 immunoprecipitation 
was performed after [3H]palmitate labeling, using a syn- 
thetic peptide against which the antibody was raised. The 
immunoprecipitation was inhibited by 10 -9 M peptide 
(Fig. 4A) at the same concentration eeded to inhibit 
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Fig. 2. Properties of GLUTl-bound palmitate. Capillary proteins were 
labeled for 3 h at 37 ° C in the presence of Triton X-100, as described in 
Fig. 1. At the end of the incubation period, the glucose transporter was 
immunoprecipitated using a polyclonal antibody directed against the 
C-terminal portion of the protein. The different lanes represent: assays 
done under standard conditions (CTL), samples incubated in 1 M 
methanolic KOH for 20 min at room temperature after immunoprecipita- 
tion (KOH) and gel that was placed in 1 M hydroxylamine (pH 7.0) for 
12 h before fluorography (NH2OH). For fluorography, the gel was 
exposed 78 days with a preflashed Kodak film. 
GLUT1 immunodetection (Fig. 4B). Densitometric scan- 
ning showed that, in both cases, 90% of the signal is 
displaced by 10 -9 M peptide. 
The effect of hyperglycemia on the palmitoylation of 
the glucose transporter was investigated by comparing the 
levels of [3H]palmitate incorporation i control rats (Co), 
streptozotocin-induced diabetic rats (Da) and diet-induced 
(50% glucose) hyperglycemic rats (Hy). Both Da and Hy 
rats lost about 50 g in body weight, while the control rats 
gained 45 g (Table 1). The plasma glucose levels of Hy 
250 
Myrlstlc Palmltlc Stearlc 
acid acid acid 
4,4 ,+ 
200 
150 
3[ n 
¢o lOO 
0 4 8 12 16 20 
Time (rain) 
Fig. 3. Identification of palmitic acid as the GLUT-linked lipid. Brain 
capillary proteins (100 ixg) were labeled with [3H]palmitate, GLUT1 was 
immunoprecipitated an  subjected to alkaline methanolysis. The released 
fatty acids were analyzed by reverse-phase HPLC as described under 
Materials and methods. The palmitate peak was identified by co-elution 
with standards. 
and Da rats were 2- and 5-fold higher than that of Co rats, 
respectively. Brain capillaries were isolated from each 
group and GLUT1 levels were measured by Western blot 
analysis. A significant reduction in GLUT1 was observed 
in capillaries isolated from diabetic rats (36%), while no 
significant change was noted in capillaries isolated from 
hyperglycemic rats (Fig. 5). Palmitoylation was evaluated 
by fluorography or gel slicing and scintillation counting. A
significant increase in palmitoylation of the glucose trans- 
porter was observed in both Da and Hy groups. Palmitate 
incorporation was increased to 152 and 138% of Co in Hy 
and Da groups, respectively. A representative fluorogram 
demonstrating this results is shown in Fig. 6. Since im- 
munodetection showed a decrease in GLUT1 expression i  
Al l  
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Fig. 4. Competitive inhibition of the immunoprecipitation of the palmitoylated GLUT1 and immunodetection by a synthetic peptide recognized by the 
antibody. (A) Capillary proteins (100 /zg) were labeled with [3H]palmitate in the presence of ATP, CoA and Mg 2+ before GLUT1 immunoprecipitation 
and separation by SDS-PAGE, as described in Fig. 1. For fluorography, the gel was exposed 62 days with a preflashed Kodak film. (B) Capillary proteins 
(1 p.g) were separated by SDS-PAGE and transferred onto a PVDF membrane. Immunodetection was performed using a polyclonal antibody directed 
against he C-terminal portion of GLUT1. Anti-GLUT1 binding was detected using a horseradish peroxidase-conjugated goat anti-rabbit IgG and detection 
performed using enhanced chemiluminescence. Competitive inhibition was performed by adding a synthetic C-terminal peptide recognized by the antibody 
in the immunoprecipitation medium (A) or by mixing the peptide with the anti-GLUT1 antibody for immunodetection (B). 
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Fig. 5. Western blot analysis of GLUT1 from different rat populations. 
Capillaries were isolated from rtormal rats (Co), streptozotocin-induced 
diabetic rats (Da) and diet-induced hyperglycemic rats (Hy). Capillary 
proteins (1 ~g) were separated by SDS-PAGE and the immunodetection 
was performed using a polyclonal anti-GLUT1 antibody, as described in 
Fig. 4. 
Fig. 6. Palmitoylation of GLUT1 in different rat populations. Freshly 
isolated capillaries from: normal rats (Co), streptozotocin-induced dia-
betic rats (Da) and diet-induced hyperglycemic rats (Hy) were incubated 
with [3H]palmitate for 3 h at 37 ° C in the presence of BSA (absence of 
Triton X-100), before GLUT1 immunoprecipitation, as described in Fig. 
1. For fluorography, the gel was exposed 102 days with a preflashed 
Kodak film. 
the Da group, the real increase in GLUT1 palmitoylation 
may be corrected to 216% of Co. 
4. Discussion 
The present results indicate that the glucose transporter 
of blood-brain barrier capillaries is covalently modified by 
palmitic acid. The lipid is attached to GLUT1 by an 
alkaline- and hydroxylamine-sensitive linkage, as are the 
majority of palmitoylated proteins [33]. The nature of the 
covalently bound palmitate was confirmed by alkaline 
hydrolysis followed by reverse phase HPLC. The exact 
location of the modification has not been determined. 
However, of the six cysteine residues present in the glu- 
cose transporter, three may represent a possible palmitoyla- 
tion site. Hydropathy analysis has suggested that Cys-201, 
-207 and -347 are located close to the cytoplasmic surface 
of the plasma membrane [19]. Such localized cysteines are 
the most common palmiLtoylation sites [21,22] and are 
found on many well-characterized palmitoylated proteins 
[15,17,34,35]. 
The specificity of the immunoprecipitation was con- 
firmed by competitive inhibition of anti-GLUT1 binding 
with a synthetic C-terminal peptide recognized by the 
antibody. This peptide inhibited both immunoprecipitation 
and immunodetection at the same concentration (1 nM), 
showing that in both cases the immunoreactive protein was 
GLUT1. 
An increase in GLUT1 palmitoylation was detected in 
both diabetics (Da) and diet-induced hyperglycemic (Hy) 
rats after immunoprecipitation f this transporter. The 
increase was specific to GLUT1 since, the palmitoylation 
profile of all other brain capillary proteins remained un- 
changed (results not shown). This increase in palmitoyla- 
tion in both Da and Hy rats does not correlate with 
GLUT1 expression since glucose transporter levels were 
decreased in diabetic rats, as previously reported [6,9,36], 
and remained unchanged in the Hy groups. Like glycemia, 
palmitoylation was stronger in Da rats than in Hy rats. 
Even if incubation was performed at 3 h which repre- 
sents the time required to reach steady state of palmitoyla- 
tion for most brain capillary substrates [25], the real 
turnover of GLUT1 palmitoylation remains unknown. No 
other studies have looked at the relative palmitoyl- 
transferase and -esterase activity present in the brain capil- 
laries. It is possible that the increased palmitoylation is the 
result of an augmentation of free cysteine residues avail- 
able for reaction with exogenous palmitate. Thus, the 
increased palmitoylation observed in vitro could result 
from a decreased in vivo palmitoylation. However, the 
Table 1 
General characteristics of the experimental groups 
Group n A weight (g) Serum glucose GLUT1 expression GLUT1 palmitoylation 
(mg/100 ml) (% of control) (% of control) a 
Control 94 +45 + 4.7 108 + 4.7 100 + 0 100 + 0 
Streptozotocin treated 15 - 52 5:5.2 * 534 +_ 28 * 64 + 5.8 * 215 5:3.3 * 
Glucose diet ?4 -47  5:3.4 * 203 + 6.7 * 89 5:3.5 152 + 11 * 
For GLUT1 expression and palraitoylation rats were divided in three groups and capillaries were purified from 5 to 7 rats. Results are means + S.E. 
* Significantly different from control value P < 0.05 (paired t-test). 
a Values were corrected for variations in GLUT1 expression i the different groups. 
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palmitoylation of the glucose transporter varied in the 
same direction in both models of hyperglycemia. This 
variation could correspond to an increased or decreased in
vivo palmitoylation. 
The role of palmitoylation in the regulation of the 
activity of the glucose transporter emains unknown. 
Palmitoylation is a post-translational process which modi- 
fies cysteine residues [33]. Cysteine modifiers (Cys- 
maleimide) have been shown to inhibit the transport activ- 
ity of GLUT1 without affecting either substrate binding or 
the ability of the carrier to change conformation [37]. 
Furthermore, palmitoylation is known to be a reversible 
process with a rapid turn over [38,39]. This suggests that 
this modification may provide a rapid mechanism by which 
glucose uptake could be decreased to prevent brain dam- 
age caused by hyperglycemia [40,41]. The implication of 
palmitoylation i GLUT1 regulation could also explain the 
observations of Kahn et al. [43] who reported an inhibition 
of GLUT1 transport activity in diabetic rats which could 
not be associated with transporter endocytosis or with a 
reduction in GLUT1 expression. However, it is difficult to 
establish a direct correlation between the level of palmitoy- 
lation and alteration of glucose transport, since the levels 
of alteration vary strongly (from 0 to 100%) between 
previous tudies and depend upon the procedure which is 
used to measure glucose transport [8,10,12,42]. 
In conclusion, this study shows that the glucose trans- 
porter (GLUT1) of brain capillaries is covalently modified 
by palmitate. Palmitoylation was increased in both diabetic 
and diet-induced hyperglycemic rats. These results uggest 
that palmitoylation may be involved in the regulation of 
GLUT1 activity when the blood glucose concentration is 
rising. 
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